Combining immune checkpoint inhibitors with therapies that target PI3K/AKT/mTOR pathway alterations, frequently found in endometrial cancers, may enhance outcomes by simultaneously addressing tumor proliferation and immune evasion mechanisms [221]. This evidence concerns the gene MTOR and endometrial cancer.